Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XmAb27564 · XENP-27564

Other · developed by Xencor

Phase 1 Most advanced trial (none active)
XNCR Developer
1 Registered trials

What is XmAb27564?

XmAb27564 is an investigational agent administered subcutaneously every two weeks at escalating dose levels. It is being studied in psoriasis and atopic dermatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XENP-27564
Drug type
Other
Therapy area
Dermatology, Immunology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
J3ED7G6XNQ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06005792 Phase 1 Psoriasis Terminated XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic DermatitisPsoriasis

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind XmAb27564

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.